Side-by-side comparison of AI visibility scores, market position, and capabilities
Scottsdale public safety technology (NASDAQ: AXON); Taser + body cameras + AI evidence management, Carbyne $625M acquisition creates Axon 911 emergency response platform, 18,000+ law enforcement customers competing with Motorola Solutions.
Axon Enterprise, Inc. is a Scottsdale, Arizona-based public safety technology company — publicly traded on NASDAQ (NASDAQ: AXON) as an S&P 500 Industrials component — developing and selling conducted energy weapons (Taser), body-worn cameras, cloud-based digital evidence management, real-time operations software, and AI-driven public safety intelligence solutions to law enforcement agencies, military organizations, and corrections facilities worldwide through approximately 5,000 employees. Axon's Taser electric weapons (used by 18,000+ law enforcement agencies in 107 countries) define the conducted energy weapon category — but Axon has expanded beyond hardware into a comprehensive cloud-based public safety software platform: Axon Evidence (body camera video storage, evidence management, and prosecutorial disclosure), Axon Records (digital police reports), Axon Dispatch (AI-assisted dispatch), and Axon Draft One (AI-generated use-of-force reports from body camera audio). In a landmark 2025 expansion, Axon announced a $625 million cash acquisition of Carbyne — an emergency communications platform serving 250+ million people worldwide through next-generation 911 call routing, real-time location data, and AI dispatch situational intelligence — creating Axon 911, an integrated emergency response platform combining cloud-native 911 call management with AI-powered context delivery for dispatchers and first responders. The Carbyne acquisition is expected to close Q1 2026. CEO Rick Smith — Axon's founder, who invented the first Taser in the early 1990s after losing two childhood friends to gun violence — leads the company's mission-driven expansion into AI-powered public safety technology.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.